CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2012-09-27): Gemcitabine-oxaliplatin combo effective in advanced liver cancer

Drug & Device Development

Gemcitabine-oxaliplatin combo effective in advanced liver cancer

Last Updated: 2012-09-27 12:45:19 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The combination of gemcitabine and oxaliplatin helped shrink large hepatomas to the point where some could be resected, in a retrospective multicenter study in France.

"Tumor responses permitted potentially curative treatment that was not initially feasible in a significant proportion of patients," Dr. Julien Taieb, with the Georges Pompidou European Hospital and University of Paris Descartes, and colleagues reported in the Journal of Hepatology online September 17.

In their paper, the authors point out that about 70% of patients with hepatocellular carcinomas (HCC) are not candidates for curative surgery at diagnosis. Sorafenib has shown encouraging results in improving survival in this population, and it's the current standard of care, but it does not induce tumor shrinkage that would permit resection aimed at cure.

Many chemotherapy regimens have been tried for advanced HCC, the authors continue, and the combination of gemcitabine and oxaliplatin (GEMOX) appears to be the most promising. The current paper describes the team's experience with the GEMOX regimen in 204 patients with advanced HCC treated between 2001 and 2010.

Forty-four percent of patients had grade 3-4 toxicities (e.g., thrombocytopenia, neutropenia, diarrhea and neuropathy) that led to discontinuation of treatment in 16% of the cohort, the investigators report.

On the other hand, the disease control rate was 66%, and tumor downstaging meant that 8.5% of the patients became eligible for curative-intent therapies, the data indicate.

Median progression free survival was 4.5 months, and median overall survival was 11 months, Dr. Taieb and colleagues found.

They could not uncover any clinical or biological factors that predicted treatment response, which was one of the independent factors associated with overall survival; others included gender and underlying cirrhosis.

"The results of this study underline the current interest of the GEMOX in a selected population of patients with advanced HCC and this chemotherapy could be indicated as a first line treatment for patients who may particularly benefit from tumor downsizing," they conclude.

"Pending the results of ongoing randomized trials comparing sorafenib plus GEMOX versus sorafenib alone," the authors add, "GEMOX may also be a therapeutic option after sorafenib discontinuation in the absence of validated second line treatment."


J Hepatol 2012.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.